Annular leukocytoclastic vasculitis associated with sorafenib administration.
Only one case of vasculitis associated with sorafenib has been reported, and the authors now present the first reported case of annular leukocytoclastic vasculitis (LCV) linked to sorafenib administration.
Najarian
David J
DJ
Department of Dermatology, University of Medicine and Dentistry of New Jersey, Somerset, NJ 08873, USA. djn6uuu@gmail.com
Packianathan
Vathani
V
Zeitouni
Nathalie C
NC
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib